DICE
Price:
$47.55
Market Cap:
$2.27B
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 int...[Read more]
Industry
Biotechnology
IPO Date
2021-09-15
Stock Exchange
NASDAQ
Ticker
DICE
According to DICE Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 56.07%. This represents a change of 3.12% compared to the average of 1.74% of the last 4 quarters.
The mean historical ROE of DICE Therapeutics, Inc. over the last ten years is 44.68%. The current 56.07% ROE has changed 25.48% with respect to the historical average. Over the past ten years (40 quarters), DICE's ROE was at its highest in in the December 2021 quarter at 15.62%. The ROE was at its lowest in in the June 2022 quarter at -7.82%.
Average
44.68%
Median
44.23%
Minimum
43.53%
Maximum
46.74%
Discovering the peaks and valleys of DICE Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.58%
Maximum Annual ROE = 46.74%
Minimum Annual Increase = -6.86%
Minimum Annual ROE = 43.53%
Year | ROE | Change |
---|---|---|
2022 | 43.53% | -6.86% |
2021 | 46.74% | 4.58% |
2020 | 44.69% | 2.12% |
The current ROE of DICE Therapeutics, Inc. (DICE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
44.99%
5-year avg
44.68%
10-year avg
44.68%
DICE Therapeutics, Inc.’s ROE is greater than Nuvalent, Inc. (-28.63%), greater than Arcellx, Inc. (-8.28%), greater than Vaxcyte, Inc. (-23.53%), greater than Viridian Therapeutics, Inc. (-45.47%), greater than Ventyx Biosciences, Inc. (-54.94%), greater than Immunocore Holdings plc (-14.67%), less than Cytokinetics, Incorporated (335.19%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Karuna Therapeutics, Inc. (-25.23%), greater than Dyne Therapeutics, Inc. (-57.46%), greater than Chinook Therapeutics, Inc. (-41.23%), greater than Pliant Therapeutics, Inc. (-48.91%), greater than Crinetics Pharmaceuticals, Inc. (-36.12%), less than Ascendis Pharma A/S (212.63%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than MoonLake Immunotherapeutics (-15.89%),
Company | ROE | Market cap |
---|---|---|
-28.63% | $6.70B | |
-8.28% | $4.57B | |
-23.53% | $11.63B | |
-45.47% | $1.56B | |
-54.94% | $220.62M | |
-14.67% | $1.58B | |
335.19% | $6.01B | |
-26.83% | $3.09B | |
-25.23% | $12.60B | |
-57.46% | $3.00B | |
-41.23% | $2.71B | |
-48.91% | $893.94M | |
-36.12% | $5.46B | |
212.63% | $7.95B | |
-32.76% | $556.35M | |
-22.40% | $1.39B | |
-32.99% | $129.77M | |
-85.39% | $352.34M | |
-15.89% | $3.43B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like DICE Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like DICE Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is DICE Therapeutics, Inc.'s ROE?
How is the ROE calculated for DICE Therapeutics, Inc. (DICE)?
What is the highest ROE for DICE Therapeutics, Inc. (DICE)?
What is the 3-year average ROE for DICE Therapeutics, Inc. (DICE)?
What is the 5-year average ROE for DICE Therapeutics, Inc. (DICE)?
How does the current ROE for DICE Therapeutics, Inc. (DICE) compare to its historical average?